Oxford Immunotec Global PLC (OXFD) Raised to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) from a sell rating to a hold rating in a report published on Wednesday, October 4th.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

Other analysts have also issued research reports about the company. Piper Jaffray Companies restated a buy rating and issued a $26.00 target price on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. Cowen and Company restated a buy rating and issued a $19.00 target price on shares of Oxford Immunotec Global PLC in a report on Thursday, September 28th. Finally, BTIG Research assumed coverage on Oxford Immunotec Global PLC in a report on Thursday, September 28th. They issued a buy rating and a $21.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. Oxford Immunotec Global PLC has an average rating of Hold and a consensus target price of $22.00.

Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at 16.43 on Wednesday. The firm’s market capitalization is $379.14 million. The company’s 50-day moving average price is $16.15 and its 200 day moving average price is $15.70. Oxford Immunotec Global PLC has a one year low of $11.88 and a one year high of $19.51.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last released its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) earnings per share for the quarter, hitting the consensus estimate of ($0.32). The business had revenue of $26.10 million during the quarter, compared to analyst estimates of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The company’s revenue was up 35.9% compared to the same quarter last year. During the same period last year, the company posted ($0.29) EPS. On average, analysts forecast that Oxford Immunotec Global PLC will post ($1.61) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://baseballnewssource.com/markets/oxford-immunotec-global-plc-oxfd-stock-rating-upgraded-by-zacks-investment-research/1697430.html.

In other news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $15.82, for a total value of $47,460.00. Following the sale, the director now directly owns 18,000 shares of the company’s stock, valued at $284,760. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Peter Edwardson sold 9,739 shares of Oxford Immunotec Global PLC stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $16.14, for a total value of $157,187.46. Following the sale, the chief operating officer now directly owns 92,905 shares in the company, valued at $1,499,486.70. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,110 shares of company stock valued at $1,523,514. 8.11% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OXFD. Teachers Advisors LLC grew its holdings in Oxford Immunotec Global PLC by 19.6% during the 4th quarter. Teachers Advisors LLC now owns 39,932 shares of the company’s stock worth $597,000 after acquiring an additional 6,550 shares during the period. Nationwide Fund Advisors grew its holdings in shares of Oxford Immunotec Global PLC by 1.9% in the 1st quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock valued at $213,000 after buying an additional 254 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Oxford Immunotec Global PLC in the 1st quarter valued at $1,135,000. Wells Fargo & Company MN grew its holdings in shares of Oxford Immunotec Global PLC by 129.2% in the 1st quarter. Wells Fargo & Company MN now owns 65,937 shares of the company’s stock valued at $1,021,000 after buying an additional 37,163 shares during the period. Finally, American International Group Inc. grew its holdings in shares of Oxford Immunotec Global PLC by 7.1% in the 1st quarter. American International Group Inc. now owns 13,668 shares of the company’s stock valued at $212,000 after buying an additional 904 shares during the period. 79.21% of the stock is owned by hedge funds and other institutional investors.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.